In late 2020, newly elected Kentucky Gov. Andy Beshear faced twin public health crises: COVID-19 killing hundreds monthly and drug overdose rates among the highest in the nation. Calling addiction a disease that breeds in isolation, Beshear worried people would stop seeking treatment for fear of contracting COVID-19.
To keep people alive, Beshear loosened Medicaid restrictions on substance abuse treatment providers. Kentucky joined more than 40 other states in allowing recovery centers to offer expensive treatment without prior approval from state Medicaid insurers—a measure designed to remove barriers to care during the pandemic.
By 2023, as the pandemic waned, most of those states restored prior authorization requirements for addiction treatment services. Kentucky did not. That year, providers offered more than 1,100 spots for long-term residential treatment, a state record and more slots per capita than any other state in the nation.
But as Medicaid bills piled up, so did warnings. In 2024 letters to Beshear's administration and during at least three public meetings, health industry experts warned that the loosened rules were enabling providers to bill excessively for subpar care linked to worse patient outcomes. By December 2025, the Kentucky attorney general's office identified Medicaid fraud in drug treatment as a primary area of concern.
In February 2025, Kentucky Medicaid Commissioner Lisa Lee told an advisory meeting that the previous year's spending on behavioral health and addiction treatment had reached $2.3 billion—a figure she described as unprecedented. Stuart Owen, who works for a Kentucky Medicaid insurer, told the same committee months earlier that much of that spending was driven by the drug treatment industry, including what he called "unscrupulous providers who are exploiting the heck out of that for money."
What the Right Is Saying
Fiscal conservatives and Medicaid reform advocates say Kentucky's experience demonstrates the dangers of loosening spending controls without adequate oversight. They argue that good intentions do not excuse the resulting fraud and abuse.
State lawmakers from both parties expressed concern about the lack of guardrails. Republican legislators in particular called for restoring prior authorization requirements to prevent what they characterized as a misuse of taxpayer dollars intended for vulnerable residents.
Critics note that while overdose deaths declined, Kentucky's spending growth far outpaced comparable states. They argue the policy created an environment where bad actors could thrive at taxpayers' expense, and that Beshear's administration was slow to respond once warnings emerged.
What the Left Is Saying
Progressive and public health advocates have largely defended Beshear's approach as a necessary expansion of access during an emergency. The governor himself has pointed to the sustained decline in Kentucky's drug overdose deaths—four consecutive years of decreases—as evidence his policy worked.
In an interview with ProPublica and the Lexington Herald-Leader, Beshear said: "If we'd gone back in time too early and changed things too drastically, how many more people would have died that we've saved? With four straight years of drug overdose decreases, they can throw blame at me. We'll talk about dollars, but there are people's kids that are still alive today because they were able to get addiction treatment services and get them quickly."
Addiction treatment advocates argue that prior authorization requirements create bureaucratic delays that can prove fatal for people seeking help. They contend that removing such barriers was the right call during a pandemic-driven mental health emergency, even if some providers exploited the system.
What the Numbers Show
Kentucky's behavioral health and addiction treatment Medicaid spending reached $2.3 billion in 2024, described by Commissioner Lee as unprecedented. The state offered more than 1,100 long-term residential treatment slots in 2023—more per capita than any other state. Overdose deaths did decline significantly between 2020 and 2025.
However, the decline was not unique to Kentucky. Tennessee and West Virginia—both states that maintained stricter Medicaid billing controls—also reported year-over-year decreases in fatal overdoses during the same period. Academic research attributes the national drop largely to declining opioid prescriptions, increased use of naloxone to reverse overdoses, and reduced fentanyl in the drug supply.
Addiction Recovery Care was Kentucky's largest treatment provider between 2019 and 2025, treating roughly one-third of Kentuckians seeking drug treatment at its peak. More than half of ARC's billed services were lower-level peer support groups—the same category that Medicaid experts warned was being abused, according to state data analyzed by ProPublica and the Lexington Herald-Leader.
The FBI has been investigating ARC for two years. The Department of Justice reached a $16 million settlement with ARC over Medicaid fraud allegations this week. Beshear has not apologized for the overall spending approach but acknowledged working to address identified fraud.
The Bottom Line
Kentucky's experiment in expanded Medicaid access produced measurable results—more people received treatment, and overdose deaths fell—but also created conditions for substantial fraud by some providers. The $16 million settlement with ARC represents a fraction of total spending that reached $2.3 billion in 2024 alone.
The debate now centers on whether the trade-off was worth it: Did expanded access save lives that would have been lost under stricter controls, or did the lack of oversight simply enrich bad actors while producing outcomes no better than those achieved by states with tighter Medicaid management? The available data suggests Kentucky's overdose decline mirrored national trends rather than resulting from its unique policy approach.
What happens next will likely involve legislative scrutiny. State lawmakers are expected to consider restoring some prior authorization requirements for addiction treatment providers, though any changes could face opposition from treatment advocates who argue such controls reduce access. Beshear has not ruled out policy adjustments but maintains his decision to keep the system open during COVID-19 was correct.